Journal article icon

Journal article

Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials

Abstract:

Objective INGR1D (INvestigating Genetic Risk for type 1 Diabetes) was a type 1 diabetes (T1D) genetic screening study established to identify participants for a primary prevention trial (POInT, Primary Oral Insulin Trial).

Methods The majority of participants were recruited by research midwives in antenatal clinics from 18 weeks’ gestation. Using the NHS Newborn Bloodspot Screening Programme (NBSP) infrastructure, participants enrolled in INGR1D ha...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1136/archdischild-2022-324270

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Research group:
Oxford Vaccine Group
Role:
Author
ORCID:
0000-0002-3195-6051
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Women's & Reproductive Health
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Research group:
Oxford Vaccine Group
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Research group:
Oxford Vaccine Group
Role:
Author
ORCID:
0000-0002-0749-8329
More by this author
Institution:
University of Oxford
Division:
MSD
Research group:
Oxford Vaccine Group
Role:
Author

Contributors

Role:
Contributor
Publisher:
BMJ Publishing Group
Journal:
Archives of Disease in Childhood More from this journal
Volume:
108
Issue:
1
Pages:
26-30
Place of publication:
England
Publication date:
2022-09-28
Acceptance date:
2022-09-09
DOI:
EISSN:
1468-2044
ISSN:
0003-9888
Pmid:
36171064

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP